Patents Assigned to ALTIF Laboratories
-
Patent number: 9193964Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: GrantFiled: January 23, 2014Date of Patent: November 24, 2015Assignees: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, ALTIF LABORATORIESInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Publication number: 20140171493Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: January 23, 2014Publication date: June 19, 2014Applicants: ALTIF LABORATORIES, TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCEInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Patent number: 8668907Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: GrantFiled: November 2, 2012Date of Patent: March 11, 2014Assignees: Tokyo Metropolitan Institute of Medical Science, Altif LaboratoriesInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Publication number: 20130064805Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: November 2, 2012Publication date: March 14, 2013Applicants: ALTIF LABORATORIES, TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCHInventors: TOKYO METROPOLITAN ORGANIZATION FOR, ALTIF LABORATORIES
-
Patent number: 8323640Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: GrantFiled: March 21, 2011Date of Patent: December 4, 2012Assignees: Tokyo Metropolitan Organization For Medical Research, Altif LaboratoriesInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Publication number: 20110171198Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: March 21, 2011Publication date: July 14, 2011Applicants: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH, ALTIF LABORATORIESInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Patent number: 7935336Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: GrantFiled: November 17, 2006Date of Patent: May 3, 2011Assignees: Tokyo Metropolitan Organization for Medical Research, ALTIF LaboratoriesInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Publication number: 20100166728Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: November 17, 2006Publication date: July 1, 2010Applicants: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH, ALTIF LABORATORIESInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
